Aeolus Files Investigational New Drug Application With US Food and Drug Administration to Enable Initiation of Human Safety Studies for the Development of AEOL 10150 as a Medical Countermeasure Against Lung Damage From Radiation Exposure
20 août 2014 13h00 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 20, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that it has filed an Investigational New Drug Application (IND) with the Division of...
Aeolus Announces Third Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development Program
15 août 2014 07h00 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 15, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces Additional Data Demonstrating Efficacy of AEOL 10150 as a Medical Countermeasure Against Exposure to Nerve Agents, Sulfur Mustard Gas and Nitrogen Mustard Gas
01 juil. 2014 07h30 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jul 1, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Data Presented at 8th Annual NIH Counteract Meeting in Denver
...
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal CEES Model of Mustard Gas Skin Exposure
18 juin 2014 10h39 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jun 18, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced the publication of data from animal model studies demonstrating the efficacy of...
Aeolus Pharmateucticals to Present at LD Micro Invitational Conference
02 juin 2014 08h00 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jun 2, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in...
Aeolus Announces Second Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development Program
15 mai 2014 19h03 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - May 15, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces First Quarter Fiscal Year 2014 Financial Results
14 févr. 2014 17h30 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Feb 14, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces Process Improvements and Positive 18 Month Stability Results for AEOL 10150 in New Formulation
13 févr. 2014 07h30 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Feb 13, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
90% reduction in manufacturing cost of drug substance achieved;...
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal Model of Lung Radiation Exposure; Models Developed for Pivotal Efficacy Studies
10 févr. 2014 07h30 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Feb 10, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Three papers published in Health Physics, Volume 106, Number 1 (January 2014)
...
Aeolus Receives Orphan Drug Designation for AEOL 10150 From U.S. FDA
23 janv. 2014 10h52 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jan 23, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...